Corbus Pharmaceuticals Holdings (CRBP) Total Liabilities (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Total Liabilities of $20.7 million for Q4 2025, up 53.83% year-over-year from $13.5 million in Q4 2024, and up 19.15% quarter-over-quarter from $17.4 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Total Liabilities (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Total Liabilities history runs 13 years deep, the most recent figure standing at $20.7 million for Q4 2025.
- In Q4 2025, Total Liabilities rose 53.83% year-over-year to $20.7 million; the TTM figure through Dec 2025 stood at $20.7 million (up 53.83% YoY), while the FY2025 annual figure was $20.7 million, up 53.83% from the prior year.
- Total Liabilities for Q4 2025 stood at $20.7 million, up from $17.4 million in the prior quarter.
- The five-year high for Total Liabilities was $48.6 million in Q1 2021, with the low at $12.8 million in Q1 2025.
- The 5-year median for Total Liabilities is $33.0 million (2022), against an average of $29.7 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities tumbled 61.99% in 2024, then jumped 53.83% in 2025.
- Corbus Pharmaceuticals Holdings' Total Liabilities stood at $38.6 million in 2021, then dropped by 13.72% to $33.3 million in 2022, then gained by 5.57% to $35.2 million in 2023, then sank by 61.76% to $13.5 million in 2024, then soared by 53.83% to $20.7 million in 2025.
- Business Quant data shows CRBP's Total Liabilities at $20.7 million in Q4 2025, $17.4 million in Q3 2025, and $14.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 10.03 Bn |
| 10 | Corbus Pharmaceuticals Holdings | 122.15 Mn | -41.12 Mn | - | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.69 Mn |
| Sep 30, 2025 | 17.37 Mn |
| Jun 30, 2025 | 14.09 Mn |
| Mar 31, 2025 | 12.83 Mn |
| Dec 31, 2024 | 13.45 Mn |
| Sep 30, 2024 | 13.67 Mn |
| Jun 30, 2024 | 26.44 Mn |
| Mar 31, 2024 | 28.78 Mn |
| Dec 31, 2023 | 35.18 Mn |
| Sep 30, 2023 | 35.97 Mn |
| Jun 30, 2023 | 34.20 Mn |
| Mar 31, 2023 | 35.19 Mn |
| Dec 31, 2022 | 33.32 Mn |
| Sep 30, 2022 | 31.88 Mn |
| Jun 30, 2022 | 32.60 Mn |
| Mar 31, 2022 | 34.52 Mn |
| Dec 31, 2021 | 38.62 Mn |
| Sep 30, 2021 | 41.95 Mn |
| Jun 30, 2021 | 43.65 Mn |
| Mar 31, 2021 | 48.63 Mn |